Consistently, itaconate improved the immunometabolic profile in microglia down-regulating FXN through Nrf2-mediated mechanism, highlighting itaconate as novel therapeutical option to improve FRDA-related inflammatory symptoms. The gene discussed is FXN; the disease is Friedreich ataxia.